NCT03380377View on ClinicalTrials.gov

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions
Antibody-mediated RejectionKidney Transplant; ComplicationsTransplant GlomerulopathyTransplant Glomerulopathy - Late FormTransplant Glomerulopathy - Early FormKidney Transplant Rejection
Interventions
DRUG

Clazakizumab

Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.

Trial Locations (1)

90048

Norko Ammerman, Los Angeles

All Listed Sponsors
lead

Stanley Jordan, MD

OTHER

NCT03380377 - Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant | Biotech Hunter | Biotech Hunter